Schroder Investment Management Group’s Travere Therapeutics TVTX Stock Holding History

Schroder Investment Management Group’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$5.94M	Buy	+214,925	New	+$6.42M	﹤0.01%	750
2025 Q4	–	Sell	-62,293	Closed	-$1.5M	–	1213
2025 Q3	$1.5M	Sell	62,293 -358,219	-85%	-$6.73M	﹤0.01%	976
2025 Q2	$6.22M	Sell	420,512 -172,512	-29%	-$2.86M	0.01%	732
2025 Q1	$11.7M	Buy	593,024 +175,771	+42%	+$3.57M	0.01%	612
2024 Q4	$7.23M	Sell	417,253 -260,199	-38%	-$4.6M	0.01%	706
2024 Q3	$9.49M	Buy	677,452 +43,051	+7%	+$449K	0.01%	671
2024 Q2	$5.21M	Buy	634,401 +530,024	+508%	+$3.57M	0.01%	774
2024 Q1	$805K	Buy	+104,377	New	+$881K	﹤0.01%	1055

Other funds holding TVTX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Schroder Investment Management Group's TVTX Position: Q1 2026 in Review

Schroder Investment Management Group opened a new position in Travere Therapeutics (TVTX) in Q1 2026: 214,925 shares worth $5.94M. The stake represents ﹤0.01% of the portfolio and ranks #750 among its holdings. This is a return to the name: Schroder Investment Management Group previously reported a position in TVTX as recently as Q3 2025.

Schroder Investment Management Group first reported a position in TVTX in Q1 2024 and has held it in 8 quarters since. The position peaked at $11.7M in Q1 2025. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

Schroder Investment Management Group held 214,925 shares of Travere Therapeutics worth $5.94M as of Q1 2026.
Travere Therapeutics was a new Schroder Investment Management Group position in Q1 2026.
Travere Therapeutics made up ﹤0.01% of Schroder Investment Management Group's portfolio in Q1 2026, its #750 holding.
Schroder Investment Management Group first reported a position in Travere Therapeutics in Q1 2024 and has held it in 8 quarters since.
Schroder Investment Management Group's Travere Therapeutics position peaked at $11.7M in Q1 2025.
260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Schroder Investment Management Group's 13F filing for Q1 2026, filed 14 May 2026.